Clinical trials for autism drugs have been plagued with problems: bad design, the wrong measures, too broad a range of participants. All that is finally starting to change.
In the case of autism, too, few drugs have proven effective in trials, and several have failed due to poor design. Just two drugs, risperidone and aripiprazole, are approved by the U.S. Food and Drug Administration (FDA) for autism and are intended to relieve irritability. A few others treat attention deficit hyperactivity disorder and epilepsy, which often accompany autism. But none have passed muster for treating the condition’s core social impairments or repetitive behaviors.
Read more here at Spectrum.
